Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Breast Cancer

High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow

Bone Marrow Transplantation volume 28, pages 1023–1029 (2001)Cite this article

Abstract

Fifty women with breast cancer metastatic to bone or bone marrow involvement on light microscopy at the time of initial evaluation were treated with high-dose chemotherapy (HDC) and peripheral blood progenitor cell (PBPC) transplantation with CD34+ cell selection using the Isolex 300i system. All patients received induction chemotherapy. PBPC were mobilized with chemotherapy and granulocyte colony-stimulating factor. The median CD34+ progenitor purity was 94.7% (range 72–98.7%) and recovery 38.4% (range 21–60%). Forty-eight hours after HDC with cyclophosphamide, cisplatin and carmustine, PBPC were reinfused. Median time to neutrophil count >0.5 × 109/l was 9 (range 9–12) days and to platelet transfusion independence 11 (4–30) days. These data demonstrate that selected CD34+ PBPCs allow rapid hematologic reconstitution after HDC. During follow-up, 23% of patients developed herpes zoster. Two patients developed cytomegalovirus infections. Three patients developed fungal infections. The development of these infections was not associated with steroid use but appeared more frequently in patients with diabetes mellitus. Seventy-four per cent of patients received steroids for pulmonary toxicity. Treatment-related mortality was 4%. Progression-free survival and overall survival at 35 months was 22.4% and 40.5%, with a median of 11.4 months and 15.4 months, respectively.

Bone Marrow Transplantation (2001) 28, 1023–1029.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 1997 15: 1870–1879

    Article  CAS  PubMed  Google Scholar 

  2. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses Bone Marrow Transplant 1997 19: 661–670

    Article  CAS  PubMed  Google Scholar 

  3. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group New Engl J Med 2000 342: 1069–1076

    Article  CAS  PubMed  Google Scholar 

  4. Ross AA, Miller GW, Moss TJ et al. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer Bone Marrow Transplant 1995 15: 929–933

    CAS  PubMed  Google Scholar 

  5. Pantel K, Cote RJ, Fodstad O . Detection and clinical importance of micrometastatic disease J Natl Cancer Inst 1999 91: 1113–1124

    Article  CAS  PubMed  Google Scholar 

  6. Fisher DC, Vredenburgh JJ, Petros WP et al. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver Bone Marrow Transplant 1998 21: 117–122

    Article  CAS  PubMed  Google Scholar 

  7. Bensinger W . Peripheral blood stem cell transplantation Cancer Treat Res 1995 76: 169–193

    Article  CAS  PubMed  Google Scholar 

  8. Passos-Coelho JL, Ross AA, Moss TJ et al. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte–macrophage colony-stimulating factor Blood 1995 85: 1138–1143

    CAS  PubMed  Google Scholar 

  9. Franklin WA, Glaspy J, Pflaumer SM et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone Blood 1999 94: 340–347

    CAS  PubMed  Google Scholar 

  10. Vredenburgh JJ, Silva O, Tyer C et al. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow J Hematother 1996 5: 57–62

    Article  CAS  PubMed  Google Scholar 

  11. Shpall EJ, Bast RC Jr, Joines WT et al. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation Bone Marrow Transplant 1991 7: 145–151

    CAS  PubMed  Google Scholar 

  12. Vescio R, Schiller G, Stewart AK et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma Blood 1999 93: 1858–1868

    CAS  PubMed  Google Scholar 

  13. Schiller G, Vescio R, Freytes C et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma Bone Marrow Transplant 1998 21: 141–145

    Article  CAS  PubMed  Google Scholar 

  14. Negrin RS, Atkinson K, Leemhuis T et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer Biol Blood Marrow Transplant 2000 6: 262–271

    Article  CAS  PubMed  Google Scholar 

  15. Zambelli A, Poggi G, Da Prada G et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion Anticancer Res 1998 18: 4705–4708

    CAS  PubMed  Google Scholar 

  16. Bensinger WI, Buckner CD, Shannon-Dorcy K et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy Blood 1996 88: 4132–4138

    CAS  PubMed  Google Scholar 

  17. Klein J, Rey P, Dansey R et al. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells Bone Marrow Transplant 1999 24: 959–963

    Article  CAS  PubMed  Google Scholar 

  18. Brugger W, Scheding S, Vogel W et al. Ex vivo manipulations of CD34+ peripheral blood progenitor cells Bone Marrow Transplant 1996 18 (Suppl. 1): S5–7

    Google Scholar 

  19. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 1988 6: 1368–1376

    Article  CAS  PubMed  Google Scholar 

  20. Mansi JL, Gogas H, Bliss JM et al. Outcome of primary-breast cancer patients with micrometastases: a long-term follow-up study Lancet 1999 354: 197–202

    Article  CAS  PubMed  Google Scholar 

  21. Vredenburgh JJ, Silva O, Broadwater G et al. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support Biol Blood Marrow Transplant 1997 3: 91–97

    CAS  PubMed  Google Scholar 

  22. Cote RJ, Rosen PP, Lesser ML et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases J Clin Oncol 1991 9: 1749–1756

    Article  CAS  PubMed  Google Scholar 

  23. Diel IJ, Kaufmann M, Goerner R et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis J Clin Oncol 1992 10: 1534–1539

    Article  CAS  PubMed  Google Scholar 

  24. Ahmed T, Kancherla R, Qureshi Z et al. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome Bone Marrow Transplant 2000 25: 1041–1045

    Article  CAS  PubMed  Google Scholar 

  25. Yanovich S, Mitsky P, Cornetta K et al. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial Bone Marrow Transplant 2000 25: 1165–1174

    Article  CAS  PubMed  Google Scholar 

  26. Madan B, Broadwater G, Rubin P et al. Improved survival with consolidation high-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) compared with observation in women with metastatic breast cancer (MBC) and only bone metastases treated with induction adriamycin, 5-fluorouracil and methotrexate (AFM): A phase III prospective ramdonized comparative trial Proc ASCO 2000 19: 48a (Abstr.)

    Google Scholar 

  27. Keever CA, Small TN, Flomenberg N et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts Blood 1989 73: 1340–1350

    CAS  PubMed  Google Scholar 

  28. Galy A, Rudraraju S, Baynes R et al. Recovery of lymphocyte and dendritic cell subsets after autologous CD34+ cell transplantation Bone Marrow Transplant 2000 25: 1249–1255

    Article  CAS  PubMed  Google Scholar 

  29. Guillaume T, Rubinstein DB, Symann M . Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation Blood 1998 92: 1471–1490

    CAS  PubMed  Google Scholar 

  30. Wingard JR, Chen DY, Burns WH et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation Blood 1988 71: 1432–1437

    CAS  PubMed  Google Scholar 

  31. Reusser P, Fisher LD, Buckner CD et al. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment Blood 1990 75: 1888–1894

    CAS  PubMed  Google Scholar 

  32. Gehling UM, Ryder JW, Hogan CJ et al. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood Exp Hematol 1997 25: 1125–1139

    CAS  PubMed  Google Scholar 

  33. Koc Y, Miller KB, Schenkein DP et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome Biol Blood Marrow Transplant 200 6: 44–49

    Article  Google Scholar 

  34. Bilgrami S, Chakraborty NG, Rodriguez-Pinero F et al. Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem cell rescue Bone Marrow Transplant 1999 23: 469–474

    Article  CAS  PubMed  Google Scholar 

  35. Wald A, Leisenring W, van Burik JA et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–1466 Comment in: J Infect Dis 1998 177: 1775–1776

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Center, Wayne State University School of Medicine, Detroit, MI, USA

    JL Klein, C Hamm, RD Dansey, C Karanes, E Abella, L Cassells, WP Peters & RD Baynes

Authors
  1. JL Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Hamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. RD Dansey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Karanes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Abella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Cassells
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. WP Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. RD Baynes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klein, J., Hamm, C., Dansey, R. et al. High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow. Bone Marrow Transplant 28, 1023–1029 (2001). https://doi.org/10.1038/sj.bmt.1703274

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703274

Keywords

This article is cited by

Search

Advanced search

Quick links